Oh, how convenient! Promotional news follows yesterday's P&D and relates the PPS increase to products not approved by the FDA--the same FDA that received Keough's complaints.

Where is the Disclaimer as to whether they were compensated?

Has anyone learned whether the company dumped the 1.2M shares reported at 4:20 yesterday?

We're on the same page! Sometimes, individual criticisms are far more about paybacks. Crazy games get played on the OTC. Sort of like, you hit on my investment, I hit on your investment.

USPTO Will Begin Publishing Patent Applications

The Secret Service worked with Keough to take down Steve Renner, the guy that retaliated against Keough.

I wouldn't bank on Otiko's version of facts. He is obviously weak on IP/Patent law and FDA rules. The FDA still reflects ViaDerma II as the registrant of Viabecline. Their business license has been revoked by Nevada.

He absolutely sucks at full disclosure.

Otiko formed ViaDerma and promoted Keough's IP in 2014--long before the USPTO Transaction History indicated negative actions (that can be reversed). The last abandonment notice was in 2015. One of the published applications indicates an Information Disclosure Statement is being considered.

THERE IS NO FINAL ACTION ON THE PUBLISHED PATENT-PENDING APPLICATIONS.

There are contracts in the case docket that tell a story.

We know there is zero reason to criticize what this CEO is building. Complaints aren't always related to the value of the investment.

Oh...one last thing, you stop ******** on **** and I'll leave you alone

The key is getting in early, and choosing tickers with solid management teams. VATE is a low-risk investment with long-term rewards.

Good luck with that crap ticker with the corrupt CEO!

The REAL reason there is no 8-K is because VDRM is NOT an SEC-Reporting Company.

Only report the SEC received is from person(s) concerned about the Doc's formation of a public company to promote Trademark and Contract protected property belonging to Steven J. Keough, an expert on IP law.

Use the same "lawsuit" info I have posted previously. I won't post daily because it is such dry/boring information with no relevance to this company's great future.

Wingen Case is 18 months old--just a month older than CGRA's stellar 17-month history of ZERO dilution. There isn't a single filing on the Docket involving this gem of a company since they were served 15 months ago. The reason is the Plaintiff's know CGRA can't be held accountable. They named a kajillion people to find one real culprit.

Oh, and, BTW, if one actually reads the Docket, one can see that CGRA advanced 30 Affirmative Defenses and filed a Counter Claim which means they can get MORE MONEY!!!

Radcliffe Docket will reflect a Motion to Dismiss mid-May. Don't lose any sleep over this one. Radcliffe didn't advance a credible complaint. Regardless, it isn't CGRA's issue. Seems he has a years-old beef with Keystone, long before CGRA changed its business focus to cannabis operations/leasing, and the new bond company.

Any thoughts on the 1.2 M share dump reported at 4:20 yesterday? Sure looks like evidence that yesterday's pump was for a dump.

It has become rather obvious this is a very high-risk investment.

Tom Shuman is the person responsible for the success of THCZ aka RMHB. I benefitted from that early run to .60 pps. That was on a float under 100k. Grisaffi is the reason I left for good. He was too sleazy.

VATE is building an A Team.

BIEI exploring potential partners in the Phillipines. Read the bio of Medical Advisor Patricio Reyes.

Dr. Reyes is board certified and a neuropathologist who is Chief Medical Officer and Board Member of the Retired National Football League Players Association. He is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. He is a Fellow of the American Academy of Neurology and was former Professor of Neurology and Neuropathology at Thomas Jefferson Medical School in Philadelphia, Pennsylvania and Professor of Neurology, Pathology and Psychiatry at Creighton University School of Medicine in Omaha, Nebraska.

Dr. Reyes is a co-founder, Chief Medical Officer and Chair of the Scientific Advisory Board of Yuma Therapeutics, Inc., a Harvard Medical School affiliated Biotechnology Company that develops new diagnostic markers and treatment for Alzheimer’s disease and traumatic brain injury. Dr. Reyes is a pioneer in the fields of Aging, Alzheimer’s disease and other neurodegenerative diseases. He established the first Dementia and Alzheimer’s disease clinic and Rapid Brain Autopsy System in the country while he was in Texas and subsequently in Pennsylvania and Nebraska. He was one of the principal investigators who worked on multiple clinical trials that led to the first US FDA approved drug for Alzheimer’s disease and the only skin patch treatment for the same disorder. He and his co-workers were one of the first to describe the olfactory deficits and their anatomical and neuropathological changes in Alzheimer’s disease.

Dr. Reyes obtained his medical degree from the University of the Philippines and started his residency in Internal Medicine and Neurology at the Philippine General Hospital.

These bios ought to be highlighted in iBox.

http://www.premierbiomedical.com/about/scientific-advisory-board

Instructions for Responding to a Notice of Abandonment

Keep in mind that companies use the Private Pair database. The Public Pair database doesn't always reflect actual events and status.

https://www.uspto.gov/patents-maintaining-patent/keeping-your-patent-alive/instructions-responding-notice-abandonment

That's Otiko's defense as presented in writing to shareholders. There is so much written evidence in Otiko's news releases and financials, along with the website claims that Diabecline was their Lead Product in February 2017, that can be used against him.

Anyone can call the USPTO, as I did, and learn there is an active dispute, no Final Action, or simply look at the Transaction History displayed below.

An Answer to Keough v. Otiko et al is on its way.

KEOUGH V. OTIKO ET AL - READ BELOW

Complaint, Jurisdiction, Statement of Claim, Irreparable Injury, Relief

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130656929

Case Summary and Detailed Discussion

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130651594

Breach of Contracts and Unauthorized Disclosure and Use of Trade Secrets

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130654231

Nope. Keough v. Otiko et al is alive and well. What we see now is an orchestrated event aka Pump & Dump.

It's also a perfect opportunity for Otiko to dump shares.

Read the Relief requested in the linked portion of Complaint.

http://investorshub.advfn.com/uimage/uploads/2017/4/20/skdcnKeoughRelief.png

The SEC has to take formal complaints seriously. In this case, ViaDerma has been misleading shareholders for three years.

Proprietary Name Diabecline is in the FDA Database under Thru Pharma aka Dakota Life Science.

Gotta love a CEO that forms a bond company to fund oil and gas operations. Audited fins for www.cgrowthcapitalbond.com will be available mid week.

New well will be ready late June.

25M in assets.

Great long-term investment opportunity.

Gotta love a CEO that issues a 68-page Annual Report with Business Plan and three-year revenue projections.

Class act here. Low float. Great long-term investment opportunity.

No trade halts have been reported. Looks like they're moving through changes related to their merger with Thru Pharma dba Dakota Life Sciences. OTC Profile was updated April 20.

The DAKOTA merger provides access to both Over-The-Counter (OTC) and prescription (Rx) pharmaceutical products and technologies. Distribution of these products will initially be into the podiatry and wound care markets, with additional markets in development.

CGrowth Capital Inc (OTCMKTS: CGRA) Is Set For Another Upswing

The last time we reviewed CGrowth Capital Inc. (OTCMKTS: CGRA) back on July 19, 2016, the stock, was range trading near the resistance level of said range at $.0186, and had support at $.009. Immediately following our review with an article entitled "On The Verge Of A Breakout,” the stock actually made a breakout to a high of $.0320 on August 2, 2016. Since then the stock has again been range bound with the same support level at $.009, near where it is trading now at $.01. This is the third price dip to the support level after hitting the initial high of the range, followed by two strong bounces to the upper part of the range. From a technical analysis perspective, the stock is in a favorable set-up for a buying opportunity. In situations such as this, having fundamentals that support the buy signal allow for a higher probability of a successful trade.

Before we delve into the fundamentals of the company, some background for those not familiar with it. CGrowth Capital Inc. is an alternative asset management company for businesses and assets focused on all aspects of mining, minerals, exploration, and commercial real estate. CGrowth Capital’s services and solutions are designed to assist land owners with monetizing undervalued assets by bringing commodities such as gold, silver, oil and gas, and dolomite to market. CGrowth Capital focuses on acquiring land assets, while also providing partners and affiliates with management services, capital, contract management and logistical services necessary for the successful execution of operations. Through wholly owned subsidiaries, the company has begun to strategically leverage real estate assets for maximum value within newly developing industries, including the cannabis industry, currently underway in Washington State.

One of CGrowth Capital’s tier 3 cannabis producing tenants, Wildfire Cannabis Company, began posting initial lease revenues on November 1, 2016, following a blockbuster performance and outdoor harvest yield. Furthermore, CGrowth Capital’s manufacturing and processing facility in Chewelah, Washington is now providing turnkey commercial leases to tenants at its Washington state location where the state has legalized cannabis. Based on initial success, expansion of both indoor and outdoor operations is inevitable.

Bill Wright, CEO of CGrowth Capital, Inc., stated, “We have been working on this leasing structure and relationships for over 18 months and that diligence and patience is now paying off. While others in this new market space are spending their time telling people what they can do, we have rolled up our sleeves and executed on what we said we would do — a first to market. This is not an adventure with overnight success — it takes time, patience, the right relationships, and a whole lot of work — but we are there now and revenues will continue to build as we expand the facilities and properties under our control.”

On the financing front, CGrowth Capital Inc increased and renewed its bond offering in the United Kingdom to £30,000,000 British Pound Sterling for its subsidiary CGrowth Capital Bond Ltd. — releasing Bond Issue 2 Series 1v1 on November 9, 2016. CGrowth Capital Bond Ltd. has issued in excess of £15,000,000 GBP subscriptions to date. The Company also opened an affiliated office in Malaysia, which will support the Company’s efforts with the bond offering and other business affairs.

The offering was completed in conjunction with management’s visit with the bond administrator, and included meetings with strategic investment groups and pension managers. With the deployment of funds received through the Company’s bond offering and the execution of numerous business initiatives, the Company is focused on continuing the momentum into 2017. Subscriptions for the bonds remain strong and are expected to continue through 2017.

During the 3rd quarter of 2017, another of the Company’s oil and gas subsidiaries, Powder River Resources, completed infrastructure improvements, well workover programs, production and wellsite facility upgrades, and extensive mapping and data collection on new drilling locations. The extensive work is projected to result in oil and gas revenue ramping up through the winter and continuing to build into 2017 and beyond. As new drilling commences, and prior workovers come online, the Company looks forward to a robust energy division.

The company recently filed its 2016 consolidated annual financials for the period ended December 31, 2016 to OTC Markets. The Company’s consolidated Total Assets increased three-fold over the prior year to nearly $25,000,000. The Company has not issued shares for the 17th consecutive month, as the Company remains committed to developing its business plan without the issuance of stock. The United Kingdom audits have been completed, which now paves the way for Company to complete US audits in preparation for additional corporate developments and uplisting. Current market capitalization stands at $3.91 million, on 391.41 million shares outstanding as of April 14, 2017. The fundamentals are also favorable, supporting the current technicals mentioned at the beginning of this article.

https://www.insiderfinancial.com/cgrowth-capital-inc-otcmkts-cgra-is-set-for-another-upswing/121783/

The SEC, FDA, and OTC Markets are aware of the claims advanced in Keough v. Otiko et al.

Read the lawsuit.

The IBox section created by Neptune (white background) is very accurate and needs to stay until this lawsuit runs its course. It conveys facts related to ViaDerma, Otiko, links to the two patent-pending application numbers for the same invention, names of competitive products based on the transdermal technology at dispute, and includes written communications from Howard Phillips and Steven Keough.

The patent-pending transdermal dispute and related contracts are subjects of pending litigation. The USPTO has not confirmed abandonment of the IP as a Final Action. An Information Disclosure Statement was submitted November 2016 and is being considered.

The Internet Archive/Way Back Machine screen captures are very important. They prove that Otiko was promoting products based on the transdermal technology at the core of this lawsuit.

The Table of IP that Otiko implies he owns is also very important. Everyone can see the two numbers of the Provisional Applications that Otiko states he submitted.

The table with Distributors is important. It shows that Otiko has a financial interest in each distributor. It provides a link to the registration of BIOGENX and a link to the DOJ article regarding the multi-million dollar tax fraud perpetuated by Otiko's friend, and BIOGENX Owner, Garrett Adams, a named Defendant in this lawsuit.

To be clear, the Addendum signed in January 2017, and added to the 2016 Annual Report with Disclosures as an Exhibit, does not grant new rights to Keough's IP. It is there to clarify and correct the misleading statements made by Otiko in prior financials and news releases.

Otiko can't sue Keough for slander, defamation, etc. for contents of a Federal Lawsuit.

No excessive shorting is happening with this ticker. The daily reports indicate typical averages for penny stocks.

http://otcshortreport.com/?index=VDRM&action=view

There is no record of a Kasten trade halt by the SEC. The company may have chosen to cease trading while they work through their transition with Dakota Life Sciences. Keough did note the merger was at risk of dissolution as a result of Otiko's actions, and institutional investor fears related to Otiko's actions.

Fundamentals are horrible here. They may have to raise the Authorized so they can sell more shares to cover legal fees. The A/S is only 60M above the O/S. They reported a Going Concern with a delinquent Note in the 200-300K area. This is no "boilerplate" verbiage. It has a real number. Some tickers express NO going concern. Otiko owes ViaDerma 300k according to the latest financial report. That number is in the A/R line.

Now Otiko is facing the possibility of an injunction to prevent him from selling products based on IP owned by Keough.

If Otiko wants to spend shareholder money challenging that assertion in his Answer to the Complaint, we can all get to the whole truth and nothing but the truth.

Doesn't bother me either way. He's not spending my money.

Keough learned Otiko was infringing on March 23 which is the first day of the DFCon educational conference where Otiko was handing out samples of Viabecline.

As of December 31, 2016, the Company was in default on the repayment of certain convertible notes and promissory notes with an aggregate principal amount of $274,917, which are immediately due and payable. The continuation of the Company as a going concern through December 31, 2017 is dependent upon the continuing financial support from its stockholders or negotiation of repayment term. Management believes the existing shareholders will provide the additional cash to meet the Company’s obligations as they become due.

These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

...and then there's the lawsuit Otiko must defend.

There is no Final Action with the patent. Below is the Transaction History.



http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130069171

The IP expert named Keough doesn't believe the patent is abandoned. The contracts are available as Exhibits to the lawsuit.

Keough v. Otiko et al

Yep! The Keough Complaint lays it all out perfectly.

The 4M Float is the reason the price is up. Been here since the acquisition. Bid sat a long time around the .01 mark.

If it ever drops there again, many will try to grab it, and it will jump right back up on one Buy. In the meantime, do not be surprised if this bottom remains.

KEOUGH V. OTIKO ET AL - READ BELOW

Complaint, Jurisdiction, Statement of Claim, Irreparable Injury, Relief

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130656929

Case Summary and Detailed Discussion

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130651594

Breach of Contracts and Unauthorized Disclosure and Use of Trade Secrets

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130654231

Steven J. Keough Bio is below. Today he is President and CEO of Kasten BioPharma OTC:PK KAST. Kasten merged with Keough's business Dakota Life Sciences in March 2017. They are bringing competitive, and likely superior, products to market from their new fulfillment center in Bridgeport, CT.

http://dakotalifesci.com

Howard Phillips required Otiko to sign an Addendum to their NON-EXCLUSIVE Patent License Agreement in January 2017. It is attached to the recent Annual Report with Disclosures as an Exhibit.

The relevant excerpts are below:





Otiko signed this Addendum! It specifically states Otiko Products will have the same ingredients as Diabecline.

Otiko advertised Diabecline as their Lead Product on their website in February 2017. This is why I researched the website history using the Internet Archive tool Wayback Machine. I placed a table with the dates and "Lead Product" in the iBox. Anyone can perform the same search and find the same results. I checked the WB yesterday and no further screen captures have occurred since February 2017.

As for the different Codes. Viabecline has two extra ingredients. The Viabecline product info hasn't been updated on Daily Med since last year.

Phillips references Viabecline/Diabecline as ONE PRODUCT (Post 13720).

The Otiko excerpt stating Keough abandoned the patent is from an email response to a shareholder.

Reference Post 13028.

The original patent filed by Steve Keough was abandoned. Keough the patent attorney for Dr. Phillips who invented the technology with my assistance. I was responsible for 90% of the data that led to the patent, HOWEVER Keough put himself on as an inventor, which wasnt true. The patent was abandoned because Keough and Dr. Phillips had a falling out. I filed a provisional patent to protect the IP.
Hope this helps clarify things.
Dr. Chris Ayo Otiko,
President & CEO
ViaDerma, Inc
Corporate Headquarters
4640 Admiralty Way Suite 500, Marina Del Rey, CA 90292
Phone: (310) 496-5744
Fax: (310) 943-1457
http://viadermalicensing.com/

I read an excerpt from an email in which Otiko stated it expired.

The Patent didn't expire. There is no Final Action in the transaction list I posted numerous times.

An Information Disclosure Statement was uploaded last November.

I actually talked to the USPTO. They referred me to the attorney listed. If it was expired, he would have given me that info.

It's an IP expert named Keough vs. 11 Defendants that knowingly, or unknowingly, participated in the creation of ViaDerma, the formulation of directly competitive products based on IP Keough acquired, or a derivative thereof (patent flooding), and/or agreed to help bring those products to market.

Within the Complaint is a request to stop the manufacturing and release of these products. In conjunction with the Complaint, the SEC, OTC Markets and the FDA have been notified.

https://www.pacermonitor.com/case/21120838/Keough_v_Otiko_et_al